- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Celgene Presents Data on Revlimid and Rituxan in Follicular Lymphoma
Celgene International presented data this weekend at the American Society of Clinical Oncology's annual meeting in Chicago regarding a randomized study comparing Revlimid (lenalidomide) plus rituximab against lenalidomide monotherapy in previously treated patients with recurrent follicular lymphoma
45 patients were given either single-agent lenalidomide (15 mg in cycle 1 and 20 mg in cycles 2-12 administered on days 1-21 of each 28-day cycle) and 44 patients were given lenalidomide (15 mg in cycle 1 and 20 mg in cycles 2-12 administered on days 1-21 of each 28-day cycle) plus rituximab (375 mg/m2 weekly for four weeks in cycle 1).
Of the 89 evaluable patients, investigators noted an objective response rate of 73% in patients getting combination therapy (with 36% seeing complete response), compared to 51% for patients receiving the single-agent lenalidomide (with13% seeing a complete response).
With a median follow-up of 1.7 years (range 0.1 -- 4.1 years), the median event-free survival (EFS) for patients in the combination arm was 2 years. Patients in the single agent arm achieved a median EFS of 1.2 years.
While the data looks good, readers should keep in mind the small number of patients, as well as the fact that Revlimid not FDA-approved for the treatment of follicular lymphoma.